• Publications
  • Influence
First microRNA mimic enters clinic
TLDR
“There seems to be a threshold system at work here above which the tumor suppression system will turn back on,” says Lammers, adding that having access to and performing analyses of tumor biopsies could help determine if such a threshold phenomenon truly is in play. Expand
Tissue engineering firms go under
  • A. Bouchie
  • Biology, Medicine
  • Nature Biotechnology
  • 1 December 2002
Coming soon: a global grid for cancer research
  • A. Bouchie
  • Medicine, Biology
  • Nature Biotechnology
  • 27 August 2004
The US NCI is spearheading efforts to create a national network for storing cancer tissue samples as well as an international informatics grid to share data. Aaron Bouchie reports.
Protein Pathways
Organic farmers sue GMO producers
  • A. Bouchie
  • Biology, Medicine
  • Nature Biotechnology
  • 1 March 2002
Nature Biotechnology's academic spinouts of 2016
Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellularExpand
First-in-class anemia drug takes aim at Amgen's dominion
  • A. Bouchie
  • Biology, Medicine
  • Nature Biotechnology
  • 1 November 2013
TLDR
The oral drug FG-4592 belongs to a new type of agent that inhibits hypoxia-inducible prolyl hydrolase (HIF-PH), which is currently in phase 3 trials to treat anemia in people with chronic kidney disease (CKD). Expand
SGLT2 inhibitors enter crowded diabetes space
  • A. Bouchie
  • Biology, Medicine
  • Nature Biotechnology
  • 10 June 2013
TLDR
Januvia, a dipeptidyl peptidase-4 (DDP-4) inhibitor, accrued over $5.7 billion in sales in 2012, including Merck’s Janumet (sitagliptin/ metformin) combination pill, however, the new drugs’ negative side effects stack up fairly high. Expand
GSK plows ahead with EMA malaria vaccine submission
  • A. Bouchie
  • Biology, Medicine
  • Nature Biotechnology
  • 1 December 2013
TLDR
“Nature biotechnology have an important role in reducing the burden of malaria over the next several years because nothing else is on the near horizon,” Birkett adds. Expand
Companies in footrace to deliver RNAi
  • A. Bouchie
  • Chemistry, Medicine
  • Nature Biotechnology
  • 7 December 2012
TLDR
A gene expression test that can help predict which patients need costly and invasive cardiac screening has netted approval for coverage from Medicare’s benefits administrator Palmetto, and CardioDx announced the completion of a $58-million financing just less than two weeks after the announcement of coverage approval. Expand
...
1
2
3
4
5
...